The European Commission (EC) has granted marketing authorisation for the world’s first liquid formulation of infliximab. 

Remsima is an intravenous liquid formulation used to treat autoimmune diseases including Crohn’s disease and ulcerative colitis. Remsima was first approved in September 2013 and launched in major EU countries in 2015 as a powder, but this development represents the first marketing authorisation of the liquid formulation. 

The approval follows a study conducted by Celltrion, the biopharmaceutical company that developed the product, evaluating operational benefits and cost savings of the Remsima liquid formulation in comparison to the powder formulation.  

Findings show that Remsima IV liquid formulation reduces the mean preparation time by approximately 51%, while cutting preparation-related costs by 20%, freeing up healthcare professionals’ resource, enabling more focus on patient care while reducing contamination risks. The liquid formulation’s vial design, approved in 100mg and 350mg, also reduces storage space requirements, supporting hospital logistics and contributing to environmental sustainability by reducing waste and energy consumption. 

“Infliximab has long been a cornerstone in the management of immune-mediated inflammatory diseases, offering significant benefits to patients and healthcare systems,” said Daniele Napolitano, IBD Nurse at CEMAD, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.  

“The approval of the new liquid formulation is welcome news, as it is expected to enhance efficiency in infusion settings, by eliminating the reconstitution step and reducing preparation time and contamination risk, allowing us to optimise resources while maintaining efficacy and safety.” 

 

Bruno Quinney, Content Team, DDW